The comparative diagnostic efficacy of BNP & NT-proBNP in Chronic kidney disease patients with complications
- PMID: 40735587
- PMCID: PMC12302115
- DOI: 10.12669/pjms.41.7.11826
The comparative diagnostic efficacy of BNP & NT-proBNP in Chronic kidney disease patients with complications
Abstract
Objective: To study the differences between the B-type Natriuretic Peptide (BNP) and the N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) values in CKD patients due to diabetes and hypertension and without CKD. Another objective was to to observe what correlation the variables of age showed with the parameters of BNP, NT-proBNP values, and with Glomerular Filtration Rate (GFR).
Methods: A case-control study was performed for six months between January to June 2024. In total 254 individuals took part in the study, with ages between 30-75 years, of which 85 were healthy controls and 169 CKD cases. CKD patients were recruited from the Department of Nephrology Jinnah Postgraduate Medical Centre (JPMC), Karachi. Diagnosis was made on the basis of raised serum urea, creatinine levels, and electrolyte imbalance. The following were excluded from participation: individuals with coronary artery disease, pregnancy, more than twice-weekly dialysis, or on steroid therapy. CKD cases were also staged according to National Kidney Foundation GFR guidelines.
Results: Among the <50-year-old participants, BNP was abnormal in 92.7% of patients (p = 0.001), while NT-proBNP was abnormal in 38.5% (p = 0.01). When BNP and NT-proBNP were compared between the same individuals, BNP detected more abnormal cases, with a statistically significant difference (p = 0.01), indicating its better diagnostic yield in this group.
Conclusion: BNP was identified as a more authentic marker than NT-proBNP in order to detect cardiovascular stress in CKD patients. Its close correlation with increasing age and decreasing GFR highlights its prognostic significance and potential role in routine cardiovascular risk assessment in CKD populations.
Keywords: B-type Natriuretic Peptide; Cardiovascular Risk; Chronic Kidney Disease; Glomerular Filtration Rate; N-terminal pro-B-type Natriuretic Peptide.
Copyright: © Pakistan Journal of Medical Sciences.
Conflict of interest statement
Conflict of interest: None.
Similar articles
-
Brain natriuretic peptide and N-terminal brain natriuretic peptide for the diagnosis of haemodynamically significant patent ductus arteriosus in preterm neonates.Cochrane Database Syst Rev. 2022 Dec 8;12(12):CD013129. doi: 10.1002/14651858.CD013129.pub2. Cochrane Database Syst Rev. 2022. PMID: 36478359 Free PMC article.
-
Comparative analysis of plasma BNP and NT-proBNP levels, and NT-proBNP/BNP ratio in patients with chronic kidney disease.Hypertens Res. 2025 Jul 1. doi: 10.1038/s41440-025-02272-2. Online ahead of print. Hypertens Res. 2025. PMID: 40595360
-
The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all-cause mortality in patients who undergo noncardiac surgery.Cochrane Database Syst Rev. 2021 Dec 21;12(12):CD013139. doi: 10.1002/14651858.CD013139.pub2. Cochrane Database Syst Rev. 2021. PMID: 34931303 Free PMC article.
-
B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review.Eur J Pediatr. 2015 Oct;174(10):1267-75. doi: 10.1007/s00431-015-2619-0. Epub 2015 Aug 23. Eur J Pediatr. 2015. PMID: 26298682
-
Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure.Evid Rep Technol Assess (Full Rep). 2006 Sep;(142):1-147. Evid Rep Technol Assess (Full Rep). 2006. PMID: 17764210 Free PMC article.
References
-
- Imtiaz S, Alam A. Epidemiology and demography of chronic kidney disease in Pakistan:a review of Pakistani literature. Pak J Kidney Dis. 2023;7(1):2–7. doi:10.53778/pjkd71209.
-
- Swapna B, Fathima K, Muwayyad H, Khanam M, Salma S, Harsha S, et al. A study to assess the associated risk of developing cardiovascular diseases in chronic kidney disease. Cell Mol Biomed Rep. 2024;4(3):150–158. doi:10.55705/cmbr.2023.420751.1184.
-
- Matsushita K, Ballew SH, Wang AYM, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022;18(11):696–707. doi:10.1038/s41581-022-00616-6. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials